- Home
- GROV vs GRML Comparison
GROV vs GRML Comparison
Compare GROV & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GROV | GRML |
|---|---|---|
| Founded | 2016 | N/A |
| Country | United States | United States |
| Employees | 295 | 5 |
| Industry | Package Goods/Cosmetics | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.8M | 51.5M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | GROV | GRML |
|---|---|---|
| Price | $1.23 | $0.39 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $1.60 | N/A |
| AVG Volume (30 Days) | 58.4K | ★ 3.0M |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.81 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.03 | $0.27 |
| 52 Week High | $1.60 | $0.55 |
Technical Indicators
Market Signals| Indicator | GROV | GRML |
|---|---|---|
| Relative Strength Index (RSI) | 50.31 | 46.43 |
| Support Level | $1.19 | $0.31 |
| Resistance Level | $1.58 | $0.43 |
| Average True Range (ATR) | 0.07 | 0.05 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 68.00 | 27.24 |
Price Performance
Historical ComparisonAbout GROV Grove Collaborative Holdings Inc.
Grove Collaborative Holdings Inc is a digital-first, sustainability-oriented consumer products innovator specializing in the development and sale of household, personal care, beauty and other consumer products with a human and environmental focus. The Company sells its products through a direct-to-consumer (DTC) platform and the Company's mobile applications, where the Company sells products from Grove-owned brands (Grove Brands) and third-parties.
About GRML Greenland Mines Ltd. Common Stock
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.